Prevalence of delta-like protein 3 expression in Merkel cell carcinoma

Rand, Jamie; Balzer, Bonnie; Frishberg, David P.; Essner, Richard; Shon, Wonwoo

doi:10.1016/j.jaad.2019.09.069

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KOC is a prognostic marker in pancreatic cancers and melanomas [ 230 , 231 ] and might be a prognostic marker for MCC. Other proteins examined in MCC include vitamin D receptor, the inhibitory ligand of the Notch receptor Delta-like protein 3 (DDL3), HIF-1α and its target genes GLUT-1, MCT4, CAIX, and vascular endothelial growth factor receptor 3 (VEGFR-3), and P-cadherin [ 232 , 233 , 234 , 235 , 236 , 237 , 238 ]. However, the viral status of the tumor was not known (vitamin D receptor), no difference between VN- and VP-MCC was found (GLUT-1, MCT4, CAIX), or there was a tendency to higher expression in VP-MCC, but the difference was not significant (DDL3, HIF1α, P-cadherin).…”

Section: Specific Biomarker For Vp-mccmentioning

confidence: 99%

Merkel Cell Polyomavirus and Merkel Cell Carcinoma

Pietropaolo¹,

Prezioso

Moens

2020

Cancers

View full text Add to dashboard Cite

Viruses are the cause of approximately 15% of all human cancers. Both RNA and DNA human tumor viruses have been identified, with Merkel cell polyomavirus being the most recent one to be linked to cancer. This virus is associated with about 80% of Merkel cell carcinomas, a rare, but aggressive cutaneous malignancy. Despite its name, the cells of origin of this tumor may not be Merkel cells. This review provides an update on the structure and life cycle, cell tropism and epidemiology of the virus and its oncogenic properties. Putative strategies to prevent viral infection or treat virus-positive Merkel cell carcinoma patients are discussed.

show abstract

Section: Specific Biomarker For Vp-mccmentioning

confidence: 99%

Merkel Cell Polyomavirus and Merkel Cell Carcinoma

Pietropaolo¹,

Prezioso

Moens

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…DLL3 is upregulated in neuroendocrine tumor and has a minimal expression in normal tissues [116]. DLL3 expression was found in 91% of MCC patients [117] and high expression of DLL3 was associated with virus-positive MCCs [118]. Rovalpituzumab tesirine, an anti-DLL3 PBD-conjugated ADC [118], showed modest antitumor activity in patients with small-cell lung carcinoma treated in third lines [119] (NCT02674568), but such anti-DLL3 ADCs could represent a potential strategy for treating viro-positive MCCs.…”

Section: Merkel Cell Carcinomamentioning

confidence: 99%

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

Esnault

Schrama

Houben

et al. 2022

Cancers

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.

show abstract

Merkel Cell Carcinoma and Immunosuppression, UV Radiation, and Merkel Cell Polyomavirus

Tribble,

Pfeiffer,

Brownell

et al. 2024

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceMerkel cell carcinoma (MCC) is a rare but aggressive skin cancer. Quantifying the contribution of major potentially modifiable risk factors to the burden of MCC may inform prevention efforts.ObjectiveTo estimate the population attributable fraction of MCC cases in the US that were attributable to major immunosuppressing conditions (eg, HIV, solid organ transplant, chronic lymphocytic leukemia [CLL]), ambient UV radiation [UVR] exposure, and Merkel cell polyomavirus [MCPyV]).Design, Setting, and ParticipantsThis epidemiological assessment combined data from population-based registries and case series and included cases of MCC that were diagnosed from January 2001 to December 2019 diagnosed in people with HIV, solid organ transplant recipients, and patients with CLL who were identified through population-based cancer registries and linkages with HIV and transplant registries. UVR-based on cloud-adjusted daily ambient UVR irradiance was merged with cancer registry data on the county of residence at diagnosis. Studies reporting the prevalence of MCPyV in MCC specimens collected in the US were combined via a meta-analysis.ExposuresHIV, solid organ transplant, CLL, UVR, and MCPyV.Main Outcomes and MeasuresPopulation attributable fraction of MCC cases attributable to major risk factors.ResultsA total of 38 020 MCCs were diagnosed in the US among xx patients (14 325 [38%] female individuals; 1586 [4%] Hispanic, 561 [1%] non-Hispanic Black, and 35 171 [93%] non-Hispanic White individuals). Compared with the general US population, MCC incidence was elevated among people with HIV (standardized incidence ratio [SIR], 2.78), organ transplant recipients (SIR, 13.1), and patients with CLL (SIR, 5.75). Due to the rarity of these conditions, only 0.2% (95% CI, 0.1%-0.3%) of MCC cases were attributable to HIV, 1.5% (95% CI, 1.4%-1.7%) to solid organ transplant, and 0.8% (95% CI, 0.5%-1.3%) to CLL. Compared with individuals of racial and ethnic minority groups, MCC incidence was elevated among non-Hispanic White individuals at lower and higher ambient UVR exposure levels (incidence rate ratios: 4.05 and 4.91, respectively, for MCC on the head and neck). Overall, 65.1% (95% CI, 63.6%-66.7%) of MCCs were attributable to UVR. Based on a meta-analysis of 19 case series, 63.8% (95% CI, 54.5%-70.9%) of MCCs were attributable to MCPyV. Studies were identified from a MEDLINE search performed on October 12, 2023.Conclusions and RelevanceThe results of this study suggest that most MCC cases in the US were attributable to ambient UVR exposure or MCPyV, with a small fraction due to immunosuppressive conditions. Efforts to lower MCC incidence could focus on limiting UVR exposure.

show abstract

Prevalence of delta-like protein 3 expression in Merkel cell carcinoma

Cited by 4 publications

References 5 publications

Merkel Cell Polyomavirus and Merkel Cell Carcinoma

Merkel Cell Polyomavirus and Merkel Cell Carcinoma

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

Merkel Cell Carcinoma and Immunosuppression, UV Radiation, and Merkel Cell Polyomavirus

Contact Info

Product

Resources

About